LIBERTEX
18.8.2022 12:58:25 CEST | Business Wire | Press release
Libertex, one of the leading online trading platforms and part of the Libertex Group founded in 1997, is entering into a multi-year partnership with Germany's most successful football club. Not only is this the first time FC Bayern has worked with an Online Trading Partner in the field of CFD and foreign exchange trading (B2C sector), but it is also the first time Libertex has sponsored a German club alongside its existing commitments in the Premier League.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005297/en/
"With over 290,000 members, FC Bayern is the sports club with the biggest membership worldwide. Like their club, the fans are particularly hungry for success, but also show themselves to be fair and level-headed after defeats, which impressed us“ says Michael Geiger, CEO of Libertex . "We are delighted to be the Official Online Trading Partner of Germany's most successful club with immediate effect."
By combining the fast-paced and exciting worlds of football and trading, the partnership allows Libertex to share its love of the game and healthy competition with its millions of customers. FC Bayern's self-image is to stand for an extreme winning mentality and a good shot of self-confidence, just like the motto - If you want to win, you have to work hard for it! Similarly, Libertex's motto 'Trade For More', as Libertex Group CMO Marios Chailis explains: "Trading also requires a certain amount of self-confidence, while being aware that arrogance has no place in trading; and you need to acquire enough knowledge to avoid making the wrong decisions. That's why we support our clients on these and other points, for example by offering a demo account and other educational material."
Andreas Jung, FC Bayern board member for marketing : “Libertex is an innovative company in an emerging global market. We look forward to building a constructive partnership with one of the leading online trading platforms for experienced traders.”
As the Official Online Trading Partner of FC Bayern, Libertex will now be part of the LED perimeter advertising at Munich's Allianz Arena and will also have a regular presence on FC Bayern's social media channels.
About Libertex
Libertex is part of the Libertex Group and is an online broker offering tradable CFDs whose underlying assets are commodities, foreign exchange, ETFs, cryptocurrencies and others.
Over the years, Libertex has received more than 40 prestigious international awards and recognitions, including "Best CFD Broker Europe" (Global Brands Magazine, 2022) and "Most Trusted Broker in Europe" (Ultimate Fintech Awards, 2021). Libertex is the Official Online Trading Partner of FC Bayern and Tottenham Hotspur FC, bringing together the exciting worlds of football and trading.
Since its inception in 1997, the Libertex Group has grown into a diverse group of companies serving millions of customers from different countries around the world.
The Libertex trading platform is used by Indication Investments Ltd, a Cypriot investment firm regulated and supervised by the Cyprus Securities and Exchange Commission (CySEC) with CIF license number 164/12.
For more information about Libertex, please visit libertex.com
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 62.2% of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
VIDEO: https://youtu.be/jCCVfHUzrDo
View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005297/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom